Abstract
Introduction
Diabetes and cancer are two of the major public health concerns in present-day society, displaying an incidence that increased dramatically over the last few years and reaching epidemic proportions. The likelihood that both diseases could occur in the same person is much higher than one might expect [1, 2] . This epidemiological detail has led scientists to search for a link between diabetes and cancer. The basic mechanisms of diabetes are defined as hyperinsulinemia, hyperglycemia, altered mechanisms of cytokine secretion and even chronic inflammation [3, 4] . These signaling anomalies have also been proven to stimulate tumor cell proliferation and block several molecular pathways of cell death [5, 6] .
Several clinical studies have already shown that the diabetic patient is prone to develop various types of cancers [7, 8] . Studies further indicated that diabetes even enhances the progression of cancer, as confirmed clinically in diabetic patients (when compared with nondiabetic subjects) who may display a poorer prognosis [9, 10] . Some evidence in diabetic patients confirms the possibility that cancer progression is influenced by the anti-diabetic Starting with the pioneering study of Evans et al [11] , which reported a potential association between metformin use and reduced cancer incidence, many clinical studies have subsequently focused on the relationship between glucose lowering therapies and cancer risk and progression. Metformin and thiazolidinediones, both glucose lowering and insulin sensitizing agents, have been recently proposed to have a positive impact consisting of decreased cancer risk and improved cancer outcomes, while insulin secretagogues and insulin based regimens might have no effect or even exert a negative effect [12, 13] . Metformin is of special importance, as it is widely used as a first line therapy for type 2 diabetes mellitus (DM). This drug has also been investigated for its possible protective effects in cancer, both due to an insulin-dependent and insulin-independent mechanism of action [14] . Thiazolidinediones, on the other hand, have been associated with various health risks, such as cardiovascular problems in the case of rosiglitazone [15] , or an increase in the risk of bladder cancer in the case of pioglitazone [16] .
An important consideration for the management of diabetic patients with cancer is to provide the best strategy for treating both conditions. Clinical studies performed on cancer patients with diabetes could provide the answer to whether specific treatments in diabetes can impact the survival of cancer patients and to determine the best treatment for these patients.
In the current paper, our purpose was to review the clinical studies dealing with the prognostic influence of glucose lowering therapies for cancer patients, with a special emphasis on metformin, and to discuss the antineoplastic mechanisms of action of this antidiabetic drug.
Data sources and search strategy
We searched the Medline/Pubmed database from January 1990 to December 2013 for articles describing and analyzing the influence of glucose lowering therapies on the prognostic outcome of diabetic patients with cancer. Our search strategy consisted in the use of the formula: ("diabetes" OR "diabetic") AND ("metformin" OR "biguanides" OR "hypoglycemic agents" OR "insulin" OR "antidiabetic medication") AND "cancer" AND ("prognosis" OR "outcome" OR "mortality" OR "survival" OR "progression").
The inclusion criteria of the articles consisted of the stratification of cancer patients depending on the diabetes treatment, the analysis of a specified type of cancer, the evaluation of cancer outcomes, the analysis of newly diagnosed cancer. The exclusion criteria consisted of studies dealing with type 1 diabetes, the omission of metformin treatment, the evaluation of the risk of developing cancer and the absence of clinical endpoints. Our search was limited to English language articles. We also searched references of the included articles.
Titles, abstracts and articles were independently reviewed by at least two of the authors of the current paper.
Effects of metformin on various types of cancer
Given the glucose lowering and insulin decreasing effects of metformin, it is reasonable to assume that metformin would have a positive role especially in cancer types associated with hyperinsulinemia, type 2 diabetes or metabolic syndrome. Clinical studies have shown an improved outcome for metformin users in several types of cancer, consisting in a longer overall survival, disease-free survival, or decreased rates of recurrences.
Digestive system cancers, such as colorectal, pancreatic and hepatic cancer, have been shown to benefit from metformin use especially for limited stage disease. In colorectal cancer, Garrett et al have shown an improvement of up to 30% in survival for metformin users, but it appears that the drug loses its beneficial effect once the cancer has progressed to stage IV [17] . In confirmation to this work, Lee et al further described an improved survival after using metformin in the clinical cases of rectal cancer, but the beneficial effect of metformin was limited to the patients that had received adjuvant chemotherapy [18] . However, after adjusting for age and stage, Cossor et al obtained that colorectal cancer survival of postmenopausal women was not influenced by metformin use when compared to women without diabetes and even compared to diabetic patients without metformin [19] . These conflicting data could be explained by a dose dependent antineoplastic effect of metformin or by the combination between metformin and other antidiabetic medication, which could decrease its beneficial effect. Support for this proposal comes from a study performed on stage I-III colorectal cancer patients, which showed that although patients receiving low-intensity metformin or metformin combined with other antidiabetic treatments did not have an improved survival compared to nonmetformin users, patients receiving exclusive high-intensity metformin had a significant reduction in colorectal cancer-specific mortality (HR, 0.44; 95% CI, 0.20-0.95) [20] .
After adjusting for glycemic values, patients with hepatocellular carcinoma treated with radiofrequency ablation and receiving metformin had a superior overall survival compared to nonmetformin users [21] .
In a similar manner, metformin users that were diagnosed with pancreatic cancer had a survival benefit of 4 months when compared to non-metformin-users, which is an important outcome considering the dismal prognosis of patients suffering from pancreatic cancer. The treatment stratification showed no impact on survival for different cancer treatments, or other anti-diabetic drugs that included insulin, sulphonylureas or even thiazolidinediones [22] . For advanced pancreatic cancer receiving chemotherapy, anti-diabetic medication had no influence in terms of survival [22] [23] [24] .
In Her2/neu positive breast cancer patients, an improved survival was noticed with the use of metformin [25] , but surprisingly the results were not confirmed in triple negative cases. Even though the data did not prove to be statistically significant, triple negative breast cancer patients that did not receive metformin were more prone to have a higher risk of distant metastases. In addition, despite employing increased doses, metformin failed to improve the final prognosis [26] .
In men with prostate cancer, the overall survival seemed to be positively influenced by both metformin and thiazolidinediones [27] . Localized prostate cancer treated with externalbeam radiation therapy was proven to have a significant benefit from metformin use, as metformin use was associated with decreased rates of biochemical recurrence, distant metastases and both specific and overall mortality. Interestingly, metformin prevented the development of castrate resistant prostate cancer after biochemical failure. The statistical analysis included various confounding factors, such as age, diabetic status, levels of prostate specific antigen, T stage, Gleason score and the use of androgen-deprivation therapy [28] . However, conflicting data are presented in another study performed on diabetics with prostate cancer treated with radical prostatectomy, where metformin use failed to improve the biochemical recurrence, systemic progression and all-cause mortality [29] . This suggests that the type of associated cancer treatment or other confounding factors not taken into account might be important in determining the relevance of metformin in cancer prognosis.
In the case of ovarian cancer, both the progression-free survival at 5 years and the overall survival were shown to be superior for metformin users when compared to nonmetformin users, or even compared to nondiabetic patients [30, 31] . The results also prove that metformin users tended to be more sensitive to platinum chemotherapy than the non-users or non-diabetics (p=0.18) [30] .
Favorable results of metformin use are also observed in patients with non-muscle invasive bladder cancer, where metformin users had a significantly decreased risk of cancer recurrence, whereas non-metformin users had increased risk of cancer recurrence and progression [32] .
Cancer types of the respiratory airways are also impacted by metformin. Contradictory results derive from two studies performed on lung cancer patients. While Tan and colleagues [33] proved that metformin users have a more favorable outcome compared to insulin users, another research study showed an increased probability of metastatic disease and a shorter survival for metformin users [34] . Also, a recent retrospective study performed on 205 patients with laryngeal squamous cell carcinoma, metformin users were proven to have an increased disease free and overall survival compared to non-metformin users and even nondiabetics. Patients of the metformin-treated group had earlier stage disease and less regional metastasis when compared to diabetics without metformin treatment [35] .
In a study performed on differentiated thyroid cancer patients, metformin appeared to inhibit cancer growth, as proven by the smaller size of thyroid tumors of metformin-treated patients compared to non-metformin diabetic users and more importantly, even compared to non-diabetic patients. Also, diabetic patients not receiving metformin had a decreased likelihood of having complete remission and increased risk of shorter progression-free survival. Notably, patients had a similar distribution within groups in terms of age, sex, body mass index, diabetes management, frequencies of multifocal tumor growth, extrathyroidal extension, and locoregional and distant metastases [36] .
Unanimous confirmation of metformin's anticancer properties is, however, difficult to achieve. This could be explained by the limitations of the retrospective clinical studies, in which several confounding factors may mask the contribution of glucose lowering agents.
Metformin impacts important pathways in cancer promotion and progression
Among the drugs used in diabetes, only insulin sensitizers, such as metformin and thiazolidinediones, have shown a beneficial effect in cancer patients. Other glucose lowering therapies, such as sulphonylureas or insulin, which maintain glucose control but do not decrease endogenous insulin secretion or insulin levels, have failed to show any beneficial effect in the survival of cancer patients. This could lead to the hypothesis that reducing hyperinsulinemia is more important than maintaining glucose control in influencing cancer outcomes.
Cancer progression is known to be influenced by hyperinsulinemia, a state promoted by the presence of intra-abdominal adipose tissue because of the continuous release of non-esterified fatty acids into the circulation [37] . As the concentration of fatty acids increases, the liver, muscles and other metabolizing tissues start to oxidize and store the available fatty acids. This leads to elevated levels of blood glucose, as its concentration in the blood increases because of low absorption, storage and metabolizing rates imposed on glucose metabolizing tissues. This forces the pancreas to secrete increasing amounts of insulin regardless of the relative hypoglycemia found in the fasting states [38] . Insulin stimulates anabolic cell activity but it also promotes cell growth either directly or indirectly by stimulating IGF-1 (insulin-like growth factor-1) synthesis and release in the circulation. Through these mechanisms, insulin may become one of the factors that drive cancer progression [38] . However, IGF-1 has more potent pro-mitotic and antiapoptotic effects than insulin. Because tumor cells commonly upregulate the expression of insulin, IGF-1 and insulin/IGF-1 hybrid receptors, they may become responsive to physiological concentrations of IGF-1, thus receiving additional stimuli to proliferate from the circulation [39] .
Metformin is widely known as a potent glucose lowering drug that decreases insulin and insulin resistance. Endogenous insulin has mitogenic and proinflammatory properties, hyperinsulinemia being associated with an increased risk of distant recurrence of cancer or cancer-related death [40, 41] . The underlying mechanisms of insulin-mediated increased proliferation involve the downstream signal transduction pathways of insulin and IGF receptors, which lead to tuberous sclerosis complex 2 dephosphorylation, which subsequently gives rise to mammalian target of rapamycin (mTOR) activation and cell proliferation [42, 43] . Metformin acts on several points in the normal insulin and insulin resistance signaling states, with further implications in cancer types associated with hyperinsulinemia, type 2 diabetes or metabolic syndrome.
By decreasing insulin levels, metformin reduces insulin signaling and, consequently, its mitogenic effects (Figure 1 ). In the liver, metformin first disrupts cellular respiration in the mitochondria, which modifies the AMP/ATP ratio and activates the AMP/ATP ratio sensor AMP-activated protein kinase (AMPK). Subsequently, AMPK activation causes a disruption in the transcription of key enzymes involved in gluconeogenesis, which further leads to reduced gluconeogenesis [44, 45] .
Metformin also decreases insulin resistance by enhancing the tyrosine kinase activity of insulin receptors, which promotes glucose transporter-mediated cell uptake of glucose. The resultant normalized glycemic levels further help reduce insulin secretion. Subsequently, lowered circulating insulin levels promote hepatic synthesis of insulin-like growth factor binding protein-1 (IGFBP1) which binds to IGF-1 and reduces signaling through insulin, IGF and insulin-IGF hybrid receptors [46] . Such receptors relay their signals through insulin receptor substrate (IRS) molecules. Signal relay through other downstream molecules ultimately leads to downstream mTOR-mediated increase in cell-cycle promoting protein activity and ultimately, to cell proliferation [42] . However, apart from reducing insulin-related mTOR signaling by decreasing circulating insulin levels, metformin may lower insulin-related signaling through direct AMPK-mediated blockage of IRS-1 activity [47] .
Given the role of metformin in impacting these pathways, it is reasonable to hypothesize that metformin would especially affect malignancies which are associated with high insulin levels, insulin resistance or have a high expression of insulin receptors, such as breast, colon and prostate cancer [48] [49] [50] . This hypothesis is supported by recent clinical studies investigating the prognostic role of metformin in cancer.
Figure 1. Metformin reduces gluconeogenesis, which subsequently reduces insulin and IGF levels and signaling, leading to reduced activity in the mTOR signaling pathway and ultimately to reduced cancer cell proliferation and growth. Metformin also modulates obesity-associated inflammation, by modifying the anti-inflammatory to pro-inflammatory cytokine level ratio.
Cancer patients with an increased body-mass index have a higher risk for worse cancer outcome because the increased adiposity promotes tumor cell proliferation, invasion and metastasis. Of high clinical importance is the central abdominal obesity, which is associated both with insulin resistance and an altered adipokine secretion [51, 52] . These signaling abnormalities intensify the metabolism of cancer cells. In postmenopausal or ovarian hormonedeficient women, adipose tissue is primarily responsible for estrogen production, by converting androgens to estrogens, via aromatase [53] . The increased circulating concentrations of estrogens may further promote the progression of hormone-dependent cancers. Moreover, apart from increasing insulin or IGF-1 receptormediated signaling, hyperinsulinemia lowers the synthesis and circulating levels of sex hormone binding globulin (SHBG). Such lowered levels of SHBG lead to increased levels of bioavailable testosterone in women and bioavailable estrogens in all patients [39] , with further implications in prostate, endometrial and breast cancer. Metformin might become crucial in the treatment of hormone-dependent cancers, due to its effects of normalizing glycemia, insulinemia and the altered secretion of certain adipokines [4, [44] [45] [46] .
Insulin resistance may also influence tumorigenesis and tumor progression through the inflammatory state induced by increased adipokine secretion which is commonly associated with the metabolic syndrome [54] . For instance, the increased leptin expression known to be commonly encountered in obesity may promote tumor growth. This is illustrated in breast cancer, in which the overexpression of leptin receptors was associated with a significantly poorer survival, as opposed to cancers with normal expression or no expression of the receptor [38] . The proinflammatory effects of leptin and other adipokines are normally offset by adiponectin, a cytokine which is exclusively secreted by the adipose tissue. While adiponectin is known to inhibit cell proliferation and improve insulin resistance [55], adiponectin secretion is inhibited by high insulin levels associated with the metabolic syndrome [37] and diabetes. Because adiponectin was shown to also inhibit angiogenesis [56] , low adiponectin concentrations in obese individuals may expose them to a higher risk of developing highly vascularized tumors [38] . This inhibition may be explained by the ability of adiponectin to stimulate LKB-1 (Liver Kinase B1) expression in cancer cells, which may render them more sensitive to metformin by facilitating AMPK activation [57] . Because metformin shifts the balance between the anti-inflammatory and inflammatory cytokines produced by the adipose tissue in the metabolic syndrome, a way to assess the effects of metformin on the immunological signaling system would be to measure markers of immunity, such as CRP (Creactive protein). This notion is highlighted in a study covering the immunity in metformintreated polycystic ovary syndrome (PCOS), in which the authors reasoned that CRP was a marker of obesity rather than inflammation in patients with PCOS. They noticed that during treatment with metformin the reduction of CRP levels preceded the reduction of IL-6 levels or insulin resistance [58] , which illustrates the antiinflammatory action of metformin. The link between metformin and inflammation might be explained by its action on Nuclear Factor κB (NF-κB) mediated proinflammatory signaling. Because metformin has been shown to block the nuclear translocation of the P65 subunit of the NF-κB transcription factor complex, and because metformin upregulates Nuclear Factor κB inhibitor alpha (IκBα), an inhibitor of NF-κB signaling [59], these facts may justify the potential use of metformin as an anticancer drug in cancers in which inflammation serves as an important promoter of cancer progression. Therefore, metformin, by inducing secretion of anti-inflammatory and antiproliferative adipokines in the adipose tissue, and by lowering inflammatory signaling pathways, may help counter the pro-mitogenic effects of insulin resistance and the metabolic syndrome.
Moreover, cancer types in which the specific anti-cancer treatments are associated with hyperinsulinemia or hyperglycemia may benefit from metformin use. Androgen deprivation therapy, used in metastatic prostate cancer, leads to hyperinsulinemia. Hyperinsulinemia will decrease the levels of sex-hormone binding proteins, which will eventually increase the level of free testosterone. All contribute to a worse cancer prognosis, which could be out-balanced by the use of the insulin sensitizer, metformin [60] .
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Conclusion
The similar results obtained by different research teams suggest that the use of metformin in the treatment of diabetic patients with certain cancer types could be of high benefit in terms of improved cancer outcomes. Moreover, for some types of cancer, such as Her2 positive breast cancer and ovarian cancer, metformin not only eliminated the negative influence of DM upon cancer, but even increased survival compared to non-diabetic patients. This strongly suggests an independent anti-tumor effect of metformin and encourages its possible applicability into drug repositioning. Still, it seems that its beneficial action is more important or even limited to nonmetastatic disease, as well as its dose dependent nature.
Metformin acts on the major diabetic mechanisms that negatively influence cancer prognosis. Therefore, metformin should be greatly considered as an important treatment for diabetic patients with cancer and not only used in the initial stages of diabetes, but associated to other anti-diabetic medications in the advanced stages of diabetes.
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